Melipharm Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

Melipharm General Information

Description

Developer of sterile medical devices intended for the treatment of acute and chronic wounds. The company's sterile medical devices are a natural product that come from the selection of honey essences whose anti-bacterial and healing properties have been validated by the researchers in the laboratory, enabling doctors to treat acute and chronic wounds based on selected monofloral honey.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Corporate Office
  • 1 avenue d'Ester
  • Cedex 3
  • 87069 Limoges
  • France
+33 07
Primary Industry
Other Devices and Supplies
Other Industries
Personal Products
Pharmaceuticals
Corporate Office
  • 1 avenue d'Ester
  • Cedex 3
  • 87069 Limoges
  • France
+33 07

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Melipharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Aug-2023 Completed Generating Revenue
3. Angel (individual) 01-Oct-2014 Completed Generating Revenue
2. Angel (individual) 24-Jan-2012 $156K $296K Completed Startup
1. Angel (individual) 27-Jul-2009 $140K $140K Completed Startup
To view Melipharm’s complete valuation and funding history, request access »

Melipharm Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
To view Melipharm’s complete cap table history, request access »

Melipharm Patents

Melipharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3020948-A1 Antimicrobial composition Active 14-May-2014
FR-3020948-B1 Antimicrobial composition Active 14-May-2014
EP-4032542-A1 Antimicrobial composition comprising a carbohydrate, glucose oxidase and zinc oxide Inactive 14-May-2014
US-20170072024-A1 Antimicrobial composition comprising a carbohydrate, glucose oxidase and zinc oxide Inactive 14-May-2014
EP-3142687-A1 Antimicrobial composition comprising a carbohydrate, glucose oxydase and zinc oxide Inactive 14-May-2014 A61K38/443
To view Melipharm’s complete patent history, request access »

Melipharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Melipharm Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Limousin Business Angels Angel Group Minority
To view Melipharm’s complete investors history, request access »

Melipharm FAQs

  • When was Melipharm founded?

    Melipharm was founded in 2009.

  • Where is Melipharm headquartered?

    Melipharm is headquartered in Limoges, France.

  • What is the size of Melipharm?

    Melipharm has 7 total employees.

  • What industry is Melipharm in?

    Melipharm’s primary industry is Other Devices and Supplies.

  • Is Melipharm a private or public company?

    Melipharm is a Private company.

  • What is Melipharm’s current revenue?

    The current revenue for Melipharm is .

  • How much funding has Melipharm raised over time?

    Melipharm has raised $296K.

  • Who are Melipharm’s investors?

    Limousin Business Angels has invested in Melipharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »